ICD-hyphen10 codes covered if selection criteria are met: C34.00 -hyphen C34.92 Malignant neoplasm of bronchus and lung [good surgical candidates] C96.6 Unifocal Langerhans-hyphencell histiocytosis [eosinophilic granuloma] D86.0 Sarcoidosis of lung [must be carefully evaluated to ensure diseases is ...
In this population-based study, patients were eligible if they had a new diagnosis of lung cancer (ICD-10 codes C33 [malignant neoplasm of the trachea] or C34 [malignant neoplasm of bronchus and lung]) between 1 January 2010 and 31 December 2017 and were at least 18 years of age at di...
This newly added entity to the fifth edition is a high-grade malignant neoplasm featuring undifferentiated or rhabdoid phenotype and deficiency of SMARCA4 (also known as BRG1), a key member of the BAF (SWI/SNF) chromatin-remodeling complex. The disease was previously known as “SMARCA4-deficient...
We used both primary and secondary discharge diagnosis codes (ICD-9 codes 162.x for malignant neoplasm of trachea bronchus and lung) to identify lung cancer, and the date of first mention was used to define time to event. The secondary discharge diagnosis codes allowed us to identify patients...
Other histologies were classified as “others”, and included carcinoid (8240/3, 8244/3 and 8249/3), pleomorphic carcinoma (8022/3), giant cell carcinoma (8031/3), adenoid cystic carcinoma (8200/3), large-cell neuroendocrine carcinoma (8013/3), and neoplasm malignant, including blastoma ...
The risk of developing second primary malignant neoplasm is higher in cancer survivors than in the general population, showing a 3.8% higher probability of developing metachronous second primary malignant neoplasm within a median follow time of 2.5 years [21]. Moreover, the 10-year cumulative risk...
(epithelial neoplasm NOS vs. adenomas and adenocarcinoma (p= 0.620)), primary site (main bronchus vs. lower lobe (p= 0.833), main bronchus vs. overlapping lesion of the lung (p= 0.680)), and metastases (bone-only vs. brain-only (p= 0.805)) at 3-year CSLCD. In comparison, there...